What did Chaihu-Shugan-San improve in rats, and does that establish human benefit?
The study provides preliminary evidence of improved stomach tissue in male rats with chemically induced chronic atrophic gastritis. After six weeks, the higher Chaihu-Shugan-San dose, 1,850 mg/kg/day, was associated with less inflammation and greater gastric gland number and thickness than the untreated disease-model group. Mean stained area indicating intestinal metaplasia—replacement of stomach lining with intestinal-type tissue—was 2.65% versus 8.31%. The lower dose showed less consistent benefits. These findings concern tissue changes in an experimental model, not symptom relief or cancer prevention in patients. The study does not establish human effectiveness, an appropriate human dose or safety.
Which reporting gaps and inconsistencies limit confidence in the rat findings?
The main results report six rats per group, making estimates imprecise despite several large observed differences. Allocation was described as random, but the sequence-generation method, allocation concealment and blinding of tissue assessment were not reported; protection against systematic differences or observer influence therefore cannot be verified. No primary outcome or sample-size calculation was identified. There are also internal inconsistencies: methods describe ten weeks of chemical exposure, whereas the discussion states sixteen, and text claims about low-dose effects on apoptosis-related proteins conflict with significance labels in Figure 4. These issues require clarification without automatically invalidating the separate tissue findings.
Do the molecular and gut-bacteria findings demonstrate how the formula works?
The findings suggest a mechanism but do not demonstrate it. Treated rats showed reduced activation of NF-κB, a regulator of inflammation, alongside changes in proteins associated with cell death. However, the study did not experimentally establish that altering this pathway was necessary for the tissue improvements. Computer docking predicted interactions between selected compounds and a pathway protein; it did not confirm binding in living tissue. Gut-bacteria analyses included only three rats per group, lacked a healthy comparison group and found no significant difference in most diversity measures. These results cannot establish that bacterial changes caused gastric repair or restored a normal microbial community.
Assessed 20 Sept 2026.
